Lack Of Facts Dooms Class Cert Over Takeda Gout Drug

By Bryan Koenig · November 28, 2022, 9:16 PM EST

A federal judge last week rejected a bid by pharmacy chain Value Drug Co. to certify a class of roughly 50 purchasers of Takeda Pharmaceuticals' anti-gout drug Colcrys alleging that the...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Opinion

Case Information

Case Title

VALUE DRUG COMPANY v. TAKEDA PHARMACEUTICALS, U.S.A., INC. et al

Case Number

Court

Pennsylvania Eastern

Nature of Suit

Other Statutes: Anti-Trust

Date Filed

August 05, 2021

Recent Articles By Bryan

July 17, 2024
Heart Doctor's Sham Suit Claims Cut From Antitrust Row
July 11, 2024
Fed. Circ. Pauses Ouster Of Teva Patents From Orange Book
July 08, 2024
Texas Anesthesia Co. Can't Pause Or Appeal Suit, FTC Says
June 27, 2024
EU High Court Upends Servier Decrease Of Pay-For-Delay Fine
June 26, 2024
Apple Watch Improvement Is 'Inferior,' Docs Tell 9th Circ.
June 13, 2024
EU Makes First Ever Formal Pharma Price-Fixing Complaint
June 12, 2024
Texas Anesthesia Co. Appealing To Duck FTC Suit To 5th Circ.
June 10, 2024
Rehab Clinics Add To MultiPlan Insurance Fixing Pile-On
May 22, 2024
Teva, Bristol-Myers Cite Bystolic Against Cancer Drug Case
May 14, 2024
FTC Cleared To Sue Texas Anesthesia Co., But Not PE Firm